Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Veloxis issues FY 2014 financial guidance in line with estimates

Wednesday, 5 Mar 2014 04:19am EST 

Veloxis Pharmaceuticals A/S:Expects to report operating loss of 60-90 million Danish crowns for FY 2014.Forecasts FY 2014 net loss to be in the range of 55-85 million Danish crowns.FY 2014 EBIT negative 59.00 million Danish crowns, net income negative 58.00 million Danish crowns - Thomson Reuters I/B/E/S Estimates.